[NCAP-Discuss] Data needed for Study 2 Harm Analysis

Thu Apr 2 14:15:36 UTC 2020

Anne,

With respect, I have to disagree that Study 1 was something to leverage.  We had an expert spend full time looking into this and she drafted a report that was approved by all of us for public comment.  To just use that report as something to leverage In my view would have been a waste of the community's money and substituting our judgement for that of the independent expert.

This is taken directly from the contractor's Statement of Work (https://community.icann.org/display/NCAP/NCAP+Working+Documents?preview=%2F79437474%2F111387705%2FNCAP+Study+1+30+May+Proposal.pdf) . I have only included the relevant tasks.

Study Tasks
4. Identify gaps in the datasets used by previous studies, resulting in a list of additional datasets or data providers that would be necessary to successfully complete Studies 2 and
3.
5. Assess the potential availability of these additional datasets.
6. Produce a report on the results of Study 1.
7. Undertake a public consultation as defined by the OCTO on the results of Study 1.
8. Evaluate and recommend to the Board how to proceed with name collision research as a
result of Study 1

This is what the contractor has done.  For us to just use all of that as something to leverage and for us to brainstorm and essentially redo Tasks 4-8 does not make sense to me when we hired an independent neutral expert that already did this work and no doubt spent a good deal of the community's money.

I may be in the minority here, but if we are going to ask the Board for yet more money to do this exercise then we need to rely on the work done when we do get the money to spend.

Jeff Neuman
Senior Vice President
Com Laude | Valideus
D: +1.703.635.7514
E: jeff.neuman at comlaude.com<mailto:jeff.neuman at comlaude.com>

From: Aikman-Scalese, Anne <AAikman at lrrc.com>
Sent: Thursday, April 2, 2020 9:34 AM
To: ncap-discuss at icann.org
Cc: James Galvin <jgalvin at afilias.info>; Patrik Fältström <paf at frobbit.se>; Jeff Neuman <jeff.neuman at comlaude.com>; Matt Larson <matt.larson at icann.org>
Subject: Data needed for Study 2 Harm Analysis

Hi all,
Regarding yesterday's conversation as to the review of the document prepared by the new third Co-Chair and Jeff Neuman's comments about that, I agree we could substitute "harm" for "danger" wherever appropriate as per Jeff's suggestion.

With respect to the notion that the document is somehow outside the parameters of our work because it was not submitted to the expert for Study 1, I had understood the scope of Study 1 to be the collection of existing studies and bodies of work and experience that analyzed name collision risk.

The Co-Chairs also wanted to stay productive as to how we would address Board questions and what would be required during Study 2 in order to answer the Board's questions.  A chart was developed and it was the discussion of that chart that led to new ideas about data that had not previously been studied that would be useful in identify the "harm".  In this regard, I had never understood that the "gap analysis' undertaken in Study 1 could be read as a limitation in relation to the scope of Study 2, which, to my knowledge, has not yet been scoped.

So I am still confused as to the notion that all data inquiries going forward into Study 2 are somehow limited by the references to the existing body of knowledge compiled in Study 1.

Thank you,
Anne

Anne E. Aikman-Scalese
Of Counsel
520.629.4428 office
520.879.4725 fax
AAikman at lrrc.com<mailto:AAikman at lrrc.com>
_____________________________
[cid:image003.png at 01D608D6.6477BA80]
Lewis Roca Rothgerber Christie LLP
One South Church Avenue, Suite 2000
Tucson, Arizona 85701-1611
lrrc.com<http://lrrc.com/>
[cid:image004.jpg at 01D608D6.6477BA80]
Because what matters
to you, matters to us.(tm)

________________________________

This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521.
________________________________
The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that the Com Laude Group does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 06181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176, having its registered office at 33 Melville Street, Edinburgh, Lothian, EH3 7JF Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, headquartered at 1751 Pinnacle Drive, Suite 600, McLean, VA 22102, USA; Com Laude (Japan) Corporation, a company registered in Japan having its registered office at Suite 319,1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan. For further information see www.comlaude.com<https://comlaude.com>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mm.icann.org/pipermail/ncap-discuss/attachments/20200402/ec41b8ea/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image002.gif
Type: image/gif
Size: 70 bytes
Desc: image002.gif
URL: <http://mm.icann.org/pipermail/ncap-discuss/attachments/20200402/ec41b8ea/image002-0001.gif>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image003.png
Type: image/png
Size: 6524 bytes
Desc: image003.png
URL: <http://mm.icann.org/pipermail/ncap-discuss/attachments/20200402/ec41b8ea/image003-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image004.jpg
Type: image/jpeg
Size: 2461 bytes
Desc: image004.jpg
URL: <http://mm.icann.org/pipermail/ncap-discuss/attachments/20200402/ec41b8ea/image004-0001.jpg>